LY-3885125 is under clinical development by Eli Lilly and Co and currently in Phase I for Non Alcoholic Fatty Liver Disease (NAFLD). According to GlobalData, Phase I drugs for Non Alcoholic Fatty Liver Disease (NAFLD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the LY-3885125 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LY-3885125 is under development for the treatment of dyslipidemia and non-alcoholic fatty liver disease (NAFLD). The drug candidate is administered through subcutaneous route.
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of LY-3885125’s drug-specific PTSR and LoA scores, buy the report here.